ELOCP29

Across TCGA pan-cancer cohorts, ELOCP29 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated ELOCP29 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ELOCP29 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ELOCP29 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LAML show a favorable association.

CHOL, THCA, and BLCA are the cancer types where ELOCP29 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.221	0.775	<.001	54	view →
THCA	DFS	Tertile	III,IV	0.528	0.876	.001	54	view →
BLCA	OS	Tertile	II,III,IV	0.623	0.393	.012	42	view →
LAML	DFS	Quartile	All	0.589	0.243	.009	16	view →
READ	OS	Tertile	III,IV	0.251	0.590	.035	15	view →
LUSC	OS	Tertile	All	0.804	0.429	.007	9	view →
THYM	OS	Tertile	All	0.863	0.982	.038	6	view →
STAD	OS	Median	IV	0.490	0.210	.043	4	view →
SARC	OS	Tertile	All	0.660	0.883	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ELOCP29–CHOL (OS)

Open the CHOL breakdown →